Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bochum
Clinical trial register · Germany

Clinical Trials in Bochum, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5042 matching records held by the registry are in this view. Synced 02 Oct 2026, 03:17 UTC
5042
Studies in scope
all four open statuses
2868
Recruiting now
open to new participants
984
Lead sponsors
across recruiting studies
Top sites
Berlin 116 Essen 57 Hamburg 56 Dresden 49 Cologne 48
Narrow the registerReset
Recruitment status
Phase
Site location
Berlin116 Essen57 Hamburg56 Dresden49 Cologne48
All 184 locations
Target enrolment
to

Trials with a site in Bochum

16 of 5042 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
AstraZeneca
Phase 3
6,950
Bad Oldesloe, Bamberg, Berlin, Bielefeld, Bochum, Bremen, Chemnitz, Cologne
2026-08-24
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2
AstraZeneca
Phase 3
1,500
Berlin, Bochum, Bünde, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg
2026-08-20
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725Obesity or Overweight
AstraZeneca
Phase 3
2,500
Berlin, Bochum, Bünde, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg
2026-08-19
Recruiting
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
NCT07619131Hypercholesterolaemia
AstraZeneca
Phase 3
600
Ahrensburg, Berlin, Bochum, Gladbeck, Hamburg, Hanover, Karlsruhe, Leipzig
2026-08-12
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
AstraZeneca
Phase 3
915
Bochum, Bonn, Dresden, Duisburg, Frankfurt am Main, Hamburg, Hanover, Herne
2026-07-16
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
NCT07664553Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
600
Amberg, Bad Oeynhausen, Berlin, Bochum, Brandenburg an der Havel, Daaden, Duisburg, Eisenach
2026-07-08
Recruiting
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803Weight Management
AstraZeneca
Phase 3
4,500
Bad Oeynhausen, Bochum, Cologne, Dresden, Falkensee, Gera, Hamburg, Leipzig
2026-06-29
Recruiting
Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)
NCT07633158Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
AstraZeneca
Observational
200
Bochum, Braunschweig, Dortmund, Dresden, Hagen, Hamburg, Heilbronn, Jena
2026-06-10
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
AstraZeneca
Phase 3
11,300
Aachen, Amberg, Bad Homburg, Bad Oeynhausen, Bamberg, Bechhofen, Berlin, Bochum
2025-03-14
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
5,000
Bad Homburg, Bamberg, Berlin, Bochum, Brandenburg an der Havel, Dresden, Essen, Friedrichsthal
2025-03-03
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Bad Berka, Berlin, Bielefeld, Bochum, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt
2024-11-27
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Bad Berka, Berlin, Bielefeld, Bochum, Chemnitz, Cologne, Essen, Esslingen am Neckar
2024-11-18
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Berlin, Bochum, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hanover, Kiel
2024-06-29
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
2,554
Aachen, Amberg, Bad Oeynhausen, Berlin, Bochum, Dresden, Essen, Falkensee
2024-03-29
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
AstraZeneca
Phase 3
863
Berlin, Bochum, Cologne, Essen, Gauting, Georgsmarienhütte, Großhansdorf, Hamburg
2023-11-09
Active, closed
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709Muscle Invasive Bladder Cancer
AstraZeneca
Phase 3
712
Bielefeld, Bochum, Cologne, Düsseldorf, Giessen, Hanover, Herne, Magdeburg
2021-08-05
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 2 October 2026. https://priyalifescience.com/clinical-trials-germany/city/bochum

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,042 studies in total at the last sync on 02 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 16 of those studies with a site in Bochum that also match the filters currently applied.

How many clinical trials are recruiting in Bochum?

12 of the 16 studies on this page are recruiting new participants as of the 02 Oct 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bochum), 16 studies
PhaseStudiesRecruitingShare
Phase 3151193.8%
Observational116.3%

Most active sponsors

Lead sponsors with the most studies (Bochum)
Lead sponsorStudiesRecruiting
AstraZeneca1612
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.